MEI Pharma Bets Big: $100M Litecoin Investment Shakes Crypto Markets

Pharma giant MEI just dropped a nine-figure bombshell—and Wall Street's pill pushers didn't see this prescription coming. Their $100 million Litecoin play marks one of 2025's most aggressive corporate crypto moves.

Why LTC? Faster transactions, lower fees, and maybe just to watch Bitcoin maximalists squirm. The silver to Bitcoin's gold just got a serious institutional bump.

Analysts whisper this could trigger a domino effect—if biotech money flows into crypto, what's next? Pension funds buying Dogecoin? Meanwhile, traditional finance bros are too busy shorting Tesla to notice the paradigm shift.

In Brief

• MEI Pharma becomes the first publicly traded biotech company to exclusively bet on Litecoin in its treasury.
• Charlie Lee, creator of Litecoin, joins the board of directors to oversee this unprecedented strategy.
• MEIP stock jumped 83%, while Litecoin gained 12% in parallel.
• Luxxfolio follows the movement, doubling its LTC reserves and betting on institutional adoption.

A Crypto Boldness Signed MEI Pharma

MEI Pharma didn’t just buy Litecoin (LTC). It built around it. This Nasdaq-listed companythrough a private investment in public equity (PIPE) transaction. Its goal?It is the first time ahas dared such a decision.

The event does not stop at the purchase. MEI also welcomed. He did not mince his words:

This partnership with GSR and MEI Pharma finally brings Litecoin’s mission into an institutional framework.

With GSR, a leader in crypto markets, as a digital asset management advisor, MEI has equipped itself with. Charlie Lee, a recognized pioneer, embodies visionary leadership. GSR, on the other hand, pilots the strategy and manages risks. The result:

LTC in Orbit, MEIP Boiling

The announcement quickly stirred up waves., temporarily reaching $108. Its transaction volume exploded. The Charlie Lee effect? Certainly. But also the institutional effect.

At the same time,reaching a peak of $9.39. The 29 million shares transaction at $3.42 each was completed, reflecting massive investor enthusiasm.

, another listed player, was not left indifferent. Since March, the company has increased its Litecoin treasury by 151.6% per share, now holding.

This confirms: Litecoin is no longer confined to individual payments. It is embedding itself into corporate strategies. It becomes a treasury tool. It becomes a trusted asset.

Litecoin: The Quiet Alternative that Packs a Punch

Why did MEI bet on Litecoin and not on Ethereum or Bitcoin? The answer is twofold: efficiency and discretion.

Litecoin was designed to be fast, secure, and decentralized – and it is exciting to see these principles now embraced by a publicly traded company like MEI.

Meanwhile, Litecoin shows. On BitPay, it sometimes even surpasses Bitcoin in transaction volume.

And beyond the technical narrative, the numbers speak:

• 12.5% increase in LTC within 24 hours after the announcement;
• 83% gain in pre-market for MEIP;
• 29.2 million shares sold at $3.42 each to finance the operation;
• 151% increase in Litecoin treasury for Luxxfolio;
• $100 million allocated exclusively to the purchase of LTC.

The message is clear: Litecoin is no longer a secondary coin. It is an investment tool, a response to volatility, a strategic alternative.

With this unprecedented investment, MEI Pharma is paving the way for a new era for altcoins in corporate finance. But Litecoin is not stopping there. It is now aiming for ETFs, as evidenced by the recently postponed SEC verdict on the Litecoin and Solana ETFs. While bitcoin settles among tech giants, LTC explores new markets. One step at a time, the gray crypto makes its way to the light.

Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.